Contraception - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Contraception - Pipeline Review, H2 2015’, provides an overview of the Contraception’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Contraception
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Contraception and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Contraception pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Contraception
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Contraception Overview 9
Therapeutics Development 10
Pipeline Products for Contraception - Overview 10
Pipeline Products for Contraception - Comparative Analysis 11
Contraception - Therapeutics under Development by Companies 12
Contraception - Therapeutics under Investigation by Universities/Institutes 13
Contraception - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Contraception - Products under Development by Companies 17
Contraception - Products under Investigation by Universities/Institutes 18
Contraception - Companies Involved in Therapeutics Development 19
Agile Therapeutics, Inc. 19
Allergan Plc 20
ANI Pharmaceuticals, Inc. 21
Antares Pharma, Inc. 22
Evofem, Inc. 23
Hydra Biosciences, Inc. 24
Ligand Pharmaceuticals, Inc. 25
Orbis Biosciences, Inc. 26
Pantarhei Bioscience BV 27
Spermatech AS 28
Contraception - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
(ethinyl estradiol + levonorgestrel) - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(nestorone + estradiol acetate) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(prasterone + estradiol + progesterone) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AG-200 ER - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AG-200 SP - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Amphora - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Drug for Male Contraception - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
EP-007 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
esterol - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
etonogestrel - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
EVE-106 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
levonorgestrel - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
LJ-102 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Monoclonal Antibody Conjugates for Contraception - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
norethindrone - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
S-003296 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
S-0101255 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecule 1 for Fertility Control - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecule 2 for Fertility Control - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule to Modulate Progesterone Receptor for Fertility Control - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules to Block CatSper1 Ion Channel for Contraception - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Synthetic Peptides for Contraception - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
tanaproget - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Contraception - Recent Pipeline Updates 67
Contraception - Dormant Projects 72
Contraception - Dormant Projects 72
Contraception - Discontinued Products 73
Contraception - Product Development Milestones 74
Featured News & Press Releases 74
Jul 13, 2015: Aquila Solutions,Partners with Evofem to Submit New Drug Application to U.S. FDA for Amphora as a Contraceptive 74
Jul 06, 2015: Evofem Submits New Drug Application to U.S. FDA for Amphora as a Contraceptive 74
Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora 74
Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch 75
Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study 75
Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla 75
Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion 76
Jun 26, 2014: Evofem Announces the Completion of the Largest Phase III Contraceptive Clinical Trial to Date 76
Jun 20, 2014: Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion Transdermal Delivery Device 77
Jul 24, 2013: Health Decisions Completes Enrollment of Evofem's 3,400-subject Global Trial of Amphora® Non-hormonal Contraceptive Gel 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80
List Of Tables
Number of Products under Development for Contraception, H2 2015 10
Number of Products under Development for Contraception - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Products under Investigation by Universities/Institutes, H2 2015 18
Contraception - Pipeline by Agile Therapeutics, Inc., H2 2015 19
Contraception - Pipeline by Allergan Plc, H2 2015 20
Contraception - Pipeline by ANI Pharmaceuticals, Inc., H2 2015 21
Contraception - Pipeline by Antares Pharma, Inc., H2 2015 22
Contraception - Pipeline by Evofem, Inc., H2 2015 23
Contraception - Pipeline by Hydra Biosciences, Inc., H2 2015 24
Contraception - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 25
Contraception - Pipeline by Orbis Biosciences, Inc., H2 2015 26
Contraception - Pipeline by Pantarhei Bioscience BV, H2 2015 27
Contraception - Pipeline by Spermatech AS, H2 2015 28
Assessment by Monotherapy Products, H2 2015 29
Assessment by Combination Products, H2 2015 30
Number of Products by Stage and Target, H2 2015 32
Number of Products by Stage and Mechanism of Action, H2 2015 34
Number of Products by Stage and Route of Administration, H2 2015 36
Number of Products by Stage and Molecule Type, H2 2015 38
Contraception Therapeutics - Recent Pipeline Updates, H2 2015 67
Contraception - Dormant Projects, H2 2015 72
Contraception - Discontinued Products, H2 2015 73
List Of Figures
Number of Products under Development for Contraception, H2 2015 10
Number of Products under Development for Contraception - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Products, H2 2015 16
Assessment by Monotherapy Products, H2 2015 29
Assessment by Combination Products, H2 2015 30
Number of Products by Targets, H2 2015 31
Number of Products by Stage and Targets, H2 2015 31
Number of Products by Mechanism of Actions, H2 2015 33
Number of Products by Stage and Mechanism of Actions, H2 2015 33
Number of Products by Routes of Administration, H2 2015 35
Number of Products by Stage and Routes of Administration, H2 2015 35
Number of Products by Molecule Types, H2 2015 37
Number of Products by Stage and Molecule Types, H2 2015 37
